Fraser Wright

Fraser Wright serves as Axovant’s Chief Technology Advisor, overseeing the company’s gene therapy initiatives. Dr. Wright is the Co-Founder and former Chief Technology Officer of Spark Therapeutics, and has over 20 years of leadership experience in the development of novel vector-based biologic products. At Spark, Fraser oversaw process development and clinical-stage manufacturing for LUXTURNA™. Prior to Spark, Fraser was the founding Scientific Director of the Clinical Vector Core Laboratory at The Children’s Hospital of Philadelphia, where he directed clinical core staff in gene therapy investigational product development, manufacture, and quality control testing for ten first-in-human viral vector investigational products including LUXTURNA™ and Kymriah®. He was also previously the Director of Development and Clinical Manufacturing at Avigen.